the aclaris therapeutics ( n=19 ) quarterly earnings call is a transitional year in which we redefined our strategy and shifted our capital allocation to focus on our immuno-inflammatory pipeline. we reported positive results from the second of two pivotal phase 3 trials from common warts and if a-101 45% is approved, it has the potential to be the first FDA approved rx product for 101. we also reported positive results from our phase 1sd/ mad trial and we are now developing a new kinase inhibitor for immuno-inflammatory diseases. we will continue to advance our additional novel kinase inhibitors, ATI-1777 and ik/txk/jak3 towards IND submissions. we will continue to advance our additional new kinase inhibitors, which are our soft- jak and ik/txk/ jak3 inhibitors towards IND submissions.